Product Description
Hydromorphone is used to relieve pain. Hydromorphone extended-release tablets are used to relieve severe pain in people who are expected to need pain medication around the clock for a long time and who cannot be treated with other medications.
Mechanisms of Action: OPRD Agonist,OPRK Agonist,OPRM Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Egypt | Estonia | Finland | France | Germany | Hungary | Iceland | Indonesia | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Portugal | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States
Approved Indications: Pain Unspecified | Pain Unspecified | Morphine Dependence | Substance Abuse Unspecified
Known Adverse Events: Dizziness | Pruritus | Flushing | Headache | Constipation
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Acute Pain|Morphine Dependence|Pain, Postoperative
Phase 1: Oncology Unspecified|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
STUDY19030022 | P3 |
Recruiting |
Acute Pain|Morphine Dependence|Pain, Postoperative |
2025-06-07 |
|
CTR20212615 | P1 |
Not yet recruiting |
Oncology Unspecified|Pain Unspecified |
None |